---
abstract: ''
authors:
- Shaughnessy, Allen
category: Clinical Review
clinical_significance: High
cme_credits: 0.0
doi: ''
evidence_level: ''
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37843954/
file_path: 2023/10/cholesterol-reducer-evolocumab-associated-with-a-nonsignific.md
issue: '4'
keywords:
- Humans
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Antibodies, Monoclonal, Humanized
- Treatment Outcome
- Anticholesteremic Agents
- Cholesterol
last_updated: '2025-08-09'
mesh_terms:
- Humans
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
- Cholesterol
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Treatment Outcome
original_format: PubMed
pages: 406-407
patient_population: Adults
peer_reviewed: true
pmid: '37843954'
processed_date: '2025-08-09'
publication_date: '2023-10-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 1
source: American family physician
specialties:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in
  Cardiovascular Mortality.
topics:
- Family Medicine
volume: '108'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37843954'
  title: Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase
    in Cardiovascular Mortality.
  authors:
  - last_name: Shaughnessy
    fore_name: Allen
    initials: F
    affiliation: Tufts University, Boston, Mass.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '108'
    issue: '4'
  publication_info:
    year: '2023'
    month: '10'
    full_date: '2023-10-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Antibodies, Monoclonal, Humanized
    major_topic: false
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
  - descriptor: Anticholesteremic Agents
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
  - descriptor: Cholesterol
    major_topic: false
  - descriptor: Cardiovascular Diseases
    major_topic: true
  - descriptor: Hydroxymethylglutaryl-CoA Reductase Inhibitors
    major_topic: true
  - descriptor: Treatment Outcome
    major_topic: false
  publication_types: *id001
---

# Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in Cardiovascular Mortality.

**Authors:** Shaughnessy, Allen

**Published in:** American family physician | Vol. 108, No. 4 | 2023-10-01

**Links:** [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37843954/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Cholesterol, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome

## Article Content

# Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in Cardiovascular Mortality.

**Authors:** Shaughnessy, Allen

**Published in:** American family physician | Vol. 108, No. 4 | 2023-10-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37843954/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Cholesterol, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37843954/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37843954/) (reference)

---

*Processed: 2025-08-09* | *PubMed Enhanced: 2025-07-30*
